SECOND OPINION: PHRMA STUDY REHASHES DEBUNKED SUPPLY CHAIN BLAME GAMES
Feb 3, 2022
Big Pharma Sidesteps Industry’s Own Price Hikes and Egregious Practices in… Read More
© 2025 CSRXP- All Rights Reserved
Second Opinion
SECOND OPINION: BIG PHARMA CEO CLAIMS “COURAGEOUS” TO PRICE UNPROVEN TREATMENT 10 TIMES ESTIMATE OF FAIR PRICE
Jan 11, 2022
Biogen Decision to Change Aduhelm Price After Public Outcry Demonstrates Big… Read More
SECOND OPINION: BIG PHARMA DOUBLES DOWN ON BLAME GAME STRATEGY AMID UNPRECEDENTED MOMENTUM TO LOWER RX PRICES
Dec 3, 2021
New PhRMA Ad Campaign Aims to Dodge Accountability, Push Pharma-Backed Rebate… Read More
SECOND OPINION: BIG PHARMA TROTS OUT BOGUS R&D DEFENSE TO OPPOSE TAX
Aug 9, 2021
Remembering Drug Companies Spend Their Profits on Shareholders and Marketing… Read More
BIG PHARMA EARNINGS WATCH: ASTRAZENECA, SANOFI, MERCK, ABBVIE, ELI LILLY & AMGEN
Aug 6, 2021
Q2 Earnings Reports Continue to Show Pandemic Price Hikes Profitable for Brand… Read More
SECOND OPINION: PHARMA-BACKED REBATE RULE WOULD HIKE SENIOR PREMIUMS, BOOST DRUG COMPANY PROFITS
Jul 22, 2021
Big Pharma Wants Implementation of Misguided Policy that Does Nothing to Lower… Read More
SECOND OPINION: PFIZER’S PHONY CALL FOR LOWER DRUG COSTS
Jun 22, 2021
CEO Sidesteps Big Pharma’s Pricing Practices; Pushes Proposals That Would… Read More
SECOND OPINION: DEBUNKING BIG PHARMA’S BOGUS INNOVATION RHETORIC
Jun 7, 2021
For far too long Big Pharma has used the excuse that research and development… Read More
SECOND OPINION: DEBUNKING BIG PHARMA’S NEW BRANDING CAMPAIGN
Apr 15, 2021
PhRMA Proposals Fail to Lower Rx Prices and Instead Benefit Drug Companies and… Read More
SECOND OPINION: PFIZER TALKS IMPORTANCE OF VACCINE AFFORDABILITY WHILE SIMULTANEOUSLY PLEDGING TO HIKE PRICES
Mar 8, 2021
Big Pharma CEO Says Price Should Never Be a Barrier After CFO Promised Company… Read More
SECOND OPINION: BIG PHARMA GAMES THE PATENT SYSTEM TO HIKE PRICES AND BOOST PROFITS — NOT ‘DRIVE INNOVATION’ OR ‘ENHANCE PATIENT ACCESS’
Oct 29, 2020
Drug Companies’ Anti-Competitive Gamesmanship Comes At Tremendous Cost To… Read More
SECOND OPINION: PHARMA-BACKED REBATE RULE WOULD INCREASE OOP COSTS AND PREMIUMS FOR SENIORS — DO NOTHING TO LOWER RX PRICES
Oct 5, 2020
Big Pharma Claims Misguided Proposal Would Benefit Patients, Facts Show It… Read More